Acadia Healthcare Company, Inc. (NASDAQ:ACHC) Given Average Rating of "Moderate Buy" by Analysts

Shares of Acadia Healthcare Company, Inc. (NASDAQ:ACHC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight research firms that are presently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $56.31.

Several research analysts recently commented on ACHC shares. KeyCorp cut their price objective on shares of Acadia Healthcare from $70.00 to $65.00 and set an "overweight" rating for the company in a report on Monday, March 3rd. Barclays downgraded shares of Acadia Healthcare from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $43.00 to $35.00 in a report on Friday, February 28th. Royal Bank of Canada cut their price target on shares of Acadia Healthcare from $64.00 to $43.00 and set an "outperform" rating for the company in a report on Monday, March 3rd. StockNews.com lowered shares of Acadia Healthcare from a "hold" rating to a "sell" rating in a research report on Monday, January 6th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Acadia Healthcare from a "hold" rating to a "buy" rating and boosted their price target for the company from $45.00 to $75.00 in a research report on Thursday, December 12th.

Remove Ads

Acadia Healthcare Stock Down 2.5 %

ACHC opened at $29.12 on Wednesday. The company has a 50 day moving average of $40.93 and a 200 day moving average of $49.36. The company has a market cap of $2.71 billion, a PE ratio of 9.55, a price-to-earnings-growth ratio of 1.46 and a beta of 1.38. Acadia Healthcare has a 12 month low of $28.09 and a 12 month high of $82.40. The company has a current ratio of 1.07, a quick ratio of 1.07 and a debt-to-equity ratio of 0.60.

Institutional Trading of Acadia Healthcare

Several hedge funds have recently added to or reduced their stakes in ACHC. Lindbrook Capital LLC lifted its stake in Acadia Healthcare by 1,342.0% in the fourth quarter. Lindbrook Capital LLC now owns 721 shares of the company's stock worth $29,000 after purchasing an additional 671 shares during the last quarter. Blue Trust Inc. raised its stake in shares of Acadia Healthcare by 69.4% during the fourth quarter. Blue Trust Inc. now owns 842 shares of the company's stock valued at $33,000 after acquiring an additional 345 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Acadia Healthcare by 40.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,040 shares of the company's stock valued at $41,000 after acquiring an additional 301 shares during the last quarter. Signaturefd LLC raised its stake in shares of Acadia Healthcare by 460.6% during the fourth quarter. Signaturefd LLC now owns 1,222 shares of the company's stock valued at $48,000 after acquiring an additional 1,004 shares during the last quarter. Finally, Fifth Third Bancorp raised its stake in shares of Acadia Healthcare by 56.0% during the fourth quarter. Fifth Third Bancorp now owns 1,264 shares of the company's stock valued at $50,000 after acquiring an additional 454 shares during the last quarter.

About Acadia Healthcare

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.